Harnessing Tissue Resident Memory T Cells for Immunotherapy of Herpes Virus Infections

NIH RePORTER · NIH · R01 · $564,908 · view on reporter.nih.gov ↗

Abstract

PROJECT SUMMARY Recent work has shown that tissue resident memory (TRM) CD8+ T cells are the first line of defense for containing reactivated HSV-2 in genital skin. Deep sequencing of these unique cells has shown their TCRs differ from the TCRs detected in PBMC of the same person sampled over time, suggesting they may be directed to as yet unidentified HSV-2 antigens. As all current immunotherapeutic vaccines for HSV-2 are designed based upon antigens derived from PBMC, defining the antigenic targets of TRM cells may enhance the efficacy of novel immunotherapeutic approaches to HSV. We have recently identified TCRs of the α and β chain of laser capture purified TRM from genital skin biopsies and utilized synthetic biology to create autologous TCRs, and shown that some of these resident CD8+ T cells found in genital skin are HSV-2 specific and are directed at targets not currently emphasized in immunotherapeutic approaches to HSV-2. This proposal utilizes single cell emulsion based bar coding technology to identify in a high-throughput unbiased approach full-length TCR α and β chains of CD8+ and CD4+ T cells with RNA/protein signatures of TRM cells in cervical and vulvar tissue, as well as PBMCs of HSV-2 infected persons. We will use synthetic biology to create “reporter” T cells that can then be evaluated for their HSV specificity using a novel HSV-1/HSV-2 vireome. Identification of these cognate antigens of the TRM population is likely to yield new approaches for vaccine design.

Key facts

NIH application ID
10160756
Project number
5R01AI134878-04
Recipient
FRED HUTCHINSON CANCER RESEARCH CENTER
Principal Investigator
Lawrence Corey
Activity code
R01
Funding institute
NIH
Fiscal year
2021
Award amount
$564,908
Award type
5
Project period
2018-06-13 → 2022-03-31